SOURCE: Medical Nutrition USA, Inc.

Medical Nutrition USA, Inc.

February 17, 2010 09:00 ET

Medical Nutrition USA Announces Fourth Quarter Sales & Preliminary Earnings Results

Fourth Quarter Branded Product Sales Increase 21%; Earnings for the Year Expected to Be $0.03 to $0.04 per Share

ENGLEWOOD, NJ--(Marketwire - February 17, 2010) - Medical Nutrition USA, Inc. (NASDAQ: MDNU), a developer and distributor of uniquely engineered, nutrition-medicine products, reported preliminary, unaudited fourth quarter and full year sales and preliminary earnings for the fiscal year ended Jan. 31, 2010. 

Total revenues for the fourth quarter increased 19 percent to $4.4 million from $3.7 million in the same period a year ago. Branded product sales for the quarter increased 21 percent to $4.1 million from $3.4 million in the same period a year ago.

Preliminary earnings per diluted share in the fourth quarter are expected to be within a range of $0.01 to $0.02 compared to a net loss of ($0.01) in the same period a year ago.

Total revenues for the year increased 17 percent to $16.0 million from $13.7 million in fiscal 2009. Branded product revenues for the year increased 19 percent to $14.8 million from $12.4 million a year ago. 

The Company expects earnings per diluted share for the fiscal year to be within a range of $0.03 to $0.04 compared to a loss of ($0.04) per diluted share in the prior year.

At January 31, 2010, cash and short term investments increased to $11.5 million from $9.7 million in the previous year; an increase of $1.8 million.

"This is our third consecutive quarter of greater than 20% increases in branded product sales and we expect that momentum to carry forward into the next fiscal year," Medical Nutrition USA Chairman and Chief Executive Officer Frank A. Newman said. 

The Company had previously forecast revenue growth of 16 to 18 percent for the year.

The company will report its complete results for the fourth quarter and the year ended Jan. 31, 2010, on April 1, 2010, followed by an earnings conference call for investors at 11:00 am (EST). The conference call dial-in number is: (866) 639-9991 (United States and Canada) or (678) 302-3571 (international).

A live webcast of the conference call can also be accessed through the company's web site at:

About Medical Nutrition USA, Inc.
Medical Nutrition USA develops and distributes products for the nutritionally at risk who are under medical supervision. Its products are used primarily in long-term care facilities, hospitals, dialysis clinics and bariatric clinics. The Company's product lines include Pro-Stat®, Fiber-Stat®, UTI-Stat™ and Diff-Stat™ as well as private label products. Additional information is available at

Forward-Looking Statements
This news release contains forward-looking statements that are subject to certain risks and uncertainties. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Risks and uncertainties that could cause or contribute to such material difference include, but are not limited to, general economic conditions, changes in customer demand, changes in trends in the nursing home, renal care, health food and bariatric surgery markets, changes in competitive pricing for products, and the impact of our competitors' new product introductions. Our future financial condition and results of operations, as well as any forward-looking statements are subject to change and inherent risk and uncertainties. Other important factors that may cause actual results to differ materially from those expressed in forward-looking statements are contained in the Medical Nutrition USA, Inc. Annual Report on Form 10-K for the year ended January 31, 2009 as filed with the Securities and Exchange Commission on April 24, 2009 and Form 10-Q for the quarter ended Oct. 31, 2009 filed on Dec. 4, 2009.

Contact Information

  • Contacts:
    Medical Nutrition USA, Inc.
    Frank J. Kimmerling
    Vice President/CFO
    Email Contact

    Investor Relations
    Adam Friedman
    212.981.2529 x18
    Email Contact